INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Inovio Pharma (INO) Tops Q4 EPS by 8c
March 1, 2021 4:19 PM ESTInovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.14), $0.08 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $5.6 million versus the consensus estimate of $1.11 million.
Dr. J. Joseph Kim, INOVIO\'s President and CEO, said, "We have had a productive fourth quarter across our DNA medicines platform, including... More
